CV6 Therapeutics is a drug development biotechnology company led by CEO Dr Robert Ladner that specializes in innovative small-molecule therapeutics for cancer and inflammatory diseases. Its lead oncology candidate, CV6-168, has completed all pre-clinical development milestones. The company plans to use recent funding to progress CV6-168 into a Phase 1a first-in-human trial in advanced cancers and to perform further scientific development work. CV6 aims to start the Phase 1a clinical trial in 2023. An inflammatory-disease asset, CV6-1271, remains in preclinical development. Mechanistically, CV6-168 induces cancer-cell DNA uracilation, which—especially when combined with thymidylate synthase inhibitors—leads to uracil-based DNA damage, cell death, and stimulation of the immune response to enhance anticancer effects.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2022